Takeda looks to Millennium for its oncology future
This article was originally published in Scrip
Having positioned Millennium as its oncology company, Takeda is looking to its $8.8 billion acquisition of the US company to drive it to a top three position in the sector eventually. But there is a long way to go to reach this target, and recent megamergers have only added to the challenge.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.